TerminatedPhase 1

Pentoxifylline for Acute Alcoholic Hepatitis (AAH)

Stopped: lack of funding

4 participantsStarted 2005-03

Plain-language summary

The goal of this study is to demonstrate the effectiveness of pentoxifylline compared to placebo in AAH while studying putative mechanisms that are plausible and testable. The main hypothesis is that pentoxifylline reduces the 90-day mortality of AAH.

Who can participate

Age range21 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Inpatient with acute alcoholic hepatitis * Model for End-Stage Liver Disease (MELD) of 15 or greater * Recent alcohol abuse Exclusion Criteria: * Recent infection * Other life threatening disease * Severe coagulopathy * Another non-alcoholic cause of liver disease

What they're measuring

Survival at 28 Days

Timeframe: 28 days

Trial details

NCT IDNCT00205049

SponsorUniversity of Wisconsin, Madison

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2006-11

Results submitted2011-08-04

View on ClinicalTrials.gov More Hepatitis, Alcoholic trials